Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | STS | P08842 | 1/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | YAP1 | P46937 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350723 | 0.93 | KDM4E (0.64) | KDM4EPKMSTSTGFBR1GPR119 | |
| SCHEMBL785861 | 0.90 | KDM4E (0.60) | KDM4EPKMSTSTGFBR1GPR119 | |
| SCHEMBL1852189 | 0.89 | KDM4E (0.59) | KDM4EPKMSTSTGFBR1GPR119 | |
| SCHEMBL18129120 | 0.88 | KDM4E (0.57) | KDM4EPKMSTSTGFBR1GPR119 | |
| SCHEMBL3979358 | 0.88 | KDM4E (0.57) | KDM4EPKMSTSTGFBR1GPR119 | |
| SCHEMBL8651537 | 0.87 | NAMPT (0.61) | KDM4EPKMSTSGPR119KEAP1 | |
| SCHEMBL5266529 | 0.87 | KDM4E (0.61) | KDM4EPKMSTSGPR119KEAP1 | |
| SCHEMBL8702720 | 0.86 | NAMPT (0.61) | KDM4EPKMSTSGPR119KEAP1 | |
| SCHEMBL856875 | 0.85 | KDM4E (0.51) | KDM4EPKMSTSGPR119KEAP1 | |
| Hydrochloric Acid SCHEMBL1856109 | 0.85 | TGFBR1 (0.57) | KDM4EPKMSTSTGFBR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913710-B2 | Benzene disulfonamide for the treatment of cancer | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) | 2021-02-09 | — | — | US | disclosed |
| US-10913710-B2 | Benzene disulfonamide for the treatment of cancer | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) | 2021-02-09 | — | — | US | disclosed |
| EP-3568391-B1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | MAX PLANCK GESELLSCHAFT (DE) | 2020-11-11 | — | — | EP | disclosed |
| EP-3568391-B1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | MAX PLANCK GESELLSCHAFT (DE) | 2020-11-11 | — | — | EP | disclosed |
| EP-3568391-A1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-11-20 | — | — | EP | disclosed |
| EP-3351544-A1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-07-25 | — | — | EP | disclosed |
| EP-3351544-A1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018130625-A1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-07-19 | — | — | WO | disclosed |
| WO-2018130625-A1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-07-19 | — | — | WO | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| US-5849732-A | Phenol compound having antioxidative activity and the process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| EP-0790240-A1 | Phenol-derivatives having pharmaceutical activity and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913710-B2 | Benzene disulfonamide for the treatment of cancer | DUSP6, DUSP26, RASSF2 | KDM4E 3162/4885PKM 3357/4885STS 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.